BENDAMUSTINE HCl

oncology product with a “low side effects” profile

FROM A RELIABLE SOURCE

BENDAMUSTINE HCl (monohydrate & anhydrous CAS 3543-75-7) is used in antitumor chemotherapy based on the alkylation mechanism. Main therapeutic area is in hematology; single dosage or in combination with Rituximab.

THERAPEUTIC INDICATION: ONCOLOGY

For the treatment of chronic lymphocytic leukemia and lymphomas.

MARKET INFORMATION

Originator: MUNDIPHARMA
Originator product: RIBOMUSTIN®
Core patent exclusivities: Patents expired

YOUR ADVANTAGES   

  • Oncology product with a “low side effects” profile
  • Good quality API with reliable supply

This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.